RNA in Drug Development - RNA as a tool and target
Venue: Four Points Sheraton Hotel
|Event Date/Time: Nov 12, 2001||End Date/Time: Nov 13, 2001|
Discover new insights as leading scientists from around the world discuss the challenges and new technologies used in the research of RNA aimed at finding more efficient targets for drug design.
- RNA interference
- Ribozyme mediated repair of mutant DNA and RNA
- Ribozyme mediated targeting of HIV RNA
- GeneBloc Technology
- Small Molecule Modulation of protein / RNA interaction
- RNA targeted bioactive ligands
- Ligand based drug discovery strategy
- Escort Aptamers as Tissue Targeting Agents
- Aptabalance Biosensors
- RNA/DNA reporter engineering: in vitro and in vivo application
- Efficient Synthesis of RNA Oligonucleotides
Petra Burgstaller, Noxxon Pharma AG; Tony Giordano, Message Pharmaceuticals; John Rossi, Beckman Research Inst. of City of Hope; Bruce Sullenger, Duke University Medical Center; Michael Blind, NascaCell GmbH; Klaus Giese, atugen AG; Richard Griffey, Ibis Therapeutics; ANADYS Pharmaceuticals; Lloyd Mitchell, Intronn LLC; Kathleen Murphy, Benitec Australia Ltd; Joseph Puglisi, Stanford University School of Medicine; Joan Robbins, Immusol; Christopher Rusconi, Duke University Medical Center; Stephen Scaringe, Dharmacon Research; Beate Schmid, Center for Advanced European and Research; Thomas Tuschl, Max Planck Institute for Biophysical Chemistry; nassim Usman, Ribozyme Pharmaceuticals; James Williamson, The Scripps Research Institute; Charles Wilson, Archemix.